Pharmaceuticals, Biotechnology and Life Sciences
The European Centre for Disease Prevention and Control (ECDC) and EMA’s COVID-19 task force (ETF) have concluded that it is too early to consider using a fourth dose of mRNA COVID-19 vaccines (Pfizer’s Comirnaty and Moderna’s Spikevax) in the general population.
Moderna, Inc. (NASDAQ:MRNA) has received approval from the U.S. Food and Drug Administration (FDA) for its amendment to the emergency use authorization (EUA) to allow for a second booster dose of its COVID-19 vaccine (mRNA-1273) at the 50 µg dose level in adults 50 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines and adults 18 years of age and older with certain kinds of immunocompromise.
Moderna, Inc. (NASDAQ:MRNA) has announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age.
Moderna, Inc. (NASDAQ:MRNA) is expanding its mRNA pipeline with two new development programs. This announcement reflects the company’s commitment to expanding its portfolio by building on Moderna’s experience with Spikevax, its COVID-19 vaccine.
National Health Regulatory Authority (NHRA) of the Kingdom of Bahrain has granted emergency use authorization for Valneva’s inactivated, adjuvanted COVID-19…
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, has announced that the Committee for Medicinal Products for…
Valneva’s subsidiary Valneva Scotland has been awarded research and development funding of up to £20 million by Scottish Enterprise. The…
With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data…
Novavax Monday said that the European Medicines Agency (EMA) has recommended granting a conditional marketing authorization for its ‘ COVID-19 vaccine.
Moderna today announced the first positive interim data from the Phase 1 study of the Company’s quadrivalent seasonal flu vaccine candidate, mRNA-1010, as it successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination at all doses tested in both younger and older adults.